BBIO
HealthcareBridgeBio Pharma, Inc. · Biotechnology · $14B
What is BridgeBio Pharma, Inc.?
BridgeBio Pharma is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for genetic diseases. Founded in 2015 and headquartered in Palo Alto, California, it operates a broad pipeline spanning multiple rare conditions.
BridgeBio advances a pipeline of roughly 30 programs targeting genetic and rare diseases — from early discovery through late-stage trials. The company generates value by licensing academic research and translating it into drug candidates, with revenue potential tied to regulatory approvals and partnership agreements rather than commercial product sales today.
BridgeBio was founded in 2015 and is headquartered in Palo Alto, California.
- Acoramidis (AG10) — late-stage TTR amyloidosis-cardiomyopathy stabilizer
- BBP-831 — selective FGFR1-3 inhibitor for pediatric achondroplasia
- BBP-631 — AAV5 gene therapy for congenital adrenal hyperplasia
- Encaleret — CaSR antagonist targeting Autosomal Dominant Hypocalcemia Type 1
Is BBIO a Good Stock to Buy?
UQS Score rates BBIO as Good overall, reflecting a mixed but forward-looking profile.
The Growth pillar stands out as the strongest dimension, consistent with a company advancing multiple late-stage programs. The Risk pillar also scores well, suggesting the pipeline breadth provides some diversification against single-asset setbacks.
The Quality pillar is rated Weak, which is common for pre-profitability biotechs but signals meaningful financial fragility that investors should weigh carefully.
See the full pillar breakdown and underlying financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BBIO pay dividends?
No — BridgeBio Pharma, Inc. does not currently pay a dividend.
BBIO does not pay a dividend. As a clinical-stage company, capital is directed toward advancing its pipeline rather than returning cash to shareholders — a standard approach for biotechs with significant ongoing R&D investment.
When does BBIO report earnings?
BridgeBio Pharma reports earnings on a quarterly cadence, consistent with US-listed equities.
Quarterly results for a company at this stage tend to center on pipeline milestones, cash runway, and collaboration updates rather than revenue growth. Investors typically watch clinical readouts as closely as financial results.
For the most recent quarter's results and upcoming reporting dates, visit BridgeBio Pharma's investor relations page directly.
BBIO Price History
+28.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in BridgeBio Pharma, Inc.?
Based on BridgeBio Pharma, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does BridgeBio Pharma do?
BridgeBio discovers and develops medicines for genetic and rare diseases. Its pipeline spans roughly 30 programs — from early research through Phase 3 — covering conditions like TTR amyloidosis, achondroplasia, and congenital adrenal hyperplasia.
Does BBIO pay dividends?
No, BBIO does not currently pay a dividend. The company reinvests available capital into its clinical pipeline, which is typical for pre-profitability biopharmaceutical companies focused on R&D.
When does BBIO report earnings?
BridgeBio reports on a standard quarterly schedule. Because our data source does not provide specific upcoming dates, check the company's investor relations page for the latest earnings calendar.
Is BBIO a good stock to buy?
UQS Score rates BBIO as Good overall. The Growth pillar is strong, reflecting pipeline momentum, while the Quality pillar is Weak — highlighting the financial risks common to clinical-stage biotechs. The full breakdown is available to Pro members.
Is BBIO overvalued?
The UQS Valuation pillar for BBIO is rated Neutral, suggesting the market is pricing the stock in line with its stage and risk profile — neither deeply discounted nor clearly stretched relative to peers.
What is BBIO's market cap bracket?
BBIO is classified as a large-cap stock, which is notable for a clinical-stage biotech and reflects significant investor expectations around its late-stage pipeline, particularly in TTR amyloidosis.
Who founded BridgeBio Pharma?
BridgeBio Pharma was founded in 2015. Founding details, including key individuals involved, are widely available through the company's public filings and official website.
Is BBIO a long-term quality investment?
As a long-term quality indicator, BBIO presents a mixed picture. Strong Growth signals and a diversified pipeline are positives, but the Weak Quality pillar reflects the financial uncertainty inherent in pre-commercial biotechs. Pro members can view the complete analysis.
Unlock Full BBIO Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings for BBIO
- ✓Access underlying financial metrics driving the Quality and Risk scores
- ✓Compare BBIO against sector peers on a standardized scoring framework
- ✓Track score changes as pipeline milestones and financials evolve
Pro Analysis
BBIO — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 52.3 | 33.3 | 42.0 | 85.0 | 67.7 | 41.8 | +0.1 |
| May 22, 2026 | 52.2 | 33.3 | 42.0 | 85.0 | 67.7 | 41.4 | +0.4 |
| May 21, 2026 | 51.8 | 33.3 | 42.0 | 85.0 | 67.7 | 38.5 | -0.1 |
| May 20, 2026 | 51.9 | 33.3 | 42.0 | 85.0 | 67.7 | 39.3 | 0.0 |
| May 19, 2026 | 51.9 | 33.3 | 42.0 | 85.0 | 67.7 | 39.5 | 0.0 |
| May 18, 2026 | 51.9 | 33.3 | 42.0 | 85.0 | 67.7 | 39.2 | -0.1 |
| May 16, 2026 | 52.0 | 33.3 | 42.0 | 85.0 | 67.7 | 39.8 | +0.1 |
| May 15, 2026 | 51.9 | 33.3 | 42.0 | 85.0 | 67.7 | 39.4 | 0.0 |
| May 14, 2026 | 51.9 | 33.3 | 42.0 | 85.0 | 67.7 | 39.7 | 0.0 |
| May 13, 2026 | 51.9 | 33.3 | 42.0 | 85.0 | 67.7 | 39.6 | -0.1 |
BBIO — Pillar Breakdown
Quality
— 33.3/100 (25%)BridgeBio Pharma, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 85.0/100 (20%)BridgeBio Pharma, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 67.7/100 (15%)BridgeBio Pharma, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 41.8/100 (15%)BridgeBio Pharma, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 42/100 (25%)BridgeBio Pharma, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BBIO.
Score Composition
Financial Data
More Stock Analysis
How is the BBIO UQS Score Calculated?
The UQS (Unified Quality Score) for BridgeBio Pharma, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses BridgeBio Pharma, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether BridgeBio Pharma, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.